Page 7 - ஸ்வ் ஆரோக்கியம் முதலீட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alchemab Therapeutics Raises £60M in Series A Financing Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round. The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company, which was created by SV Health Investors who led the Seed round in 2019, intends to use the advance its target-agnostic drug discovery platform. Founded in 2019 and led by Alex Leech, CEO, and Dr Jane Osbourn OBE, CSO, Alchemab has developed a platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody re

United kingdomSv health investorsDementia discovery fundAlchemab therapeuticsUnited kingdom basedLightstone venturesData collectiveDementia discoveryAlex leechஒன்றுபட்டது கிஂக்டம்ஸ்வ் ஆரோக்கியம் முதலீட்டாளர்கள்முதுமை கண்டுபிடிப்பு நிதிஒன்றுபட்டது கிஂக்டம் அடிப்படையிலானதுதகவல்கள் கூட்டுமுதுமை கண்டுபிடிப்புஅலெக்ஸ் லீச்